Skip to main content

eSUN

MaterialsShenzhen, ChinaFounded 2002· One of 971 Materials companies tracked by AMPulse

A global leader in bio-materials and 3D printing, specializing in the research, production, and sale of high-quality filaments, resins, and biodegradable polymers like PLA and PCL.

CEO / Founder
Yang Yihu (Kevin Yang)
Team Size
501-1000
Stage
Active
Total Funding
$15.0M
Latest Round
Strategic Investment
Key Investors
SCGC (深创投), Dongxing Securities

Technology & Products

Key Products

W200 water-washable resin, PETG-ESD, high-speed filaments

Technological Advantage

Maintains a first-mover advantage as the primary drafting unit for China's national standards for PLA 3D printing consumables; holds the world's first patent for bio-based photopolymer resins.

Differentiation

Value Proposition

Delivers a 'Green' closed-loop ecosystem by vertically integrating the synthesis, modification, application, and recycling of bio-based materials, offering professional-grade performance at a competitive cost.

How They Differentiate

Vertical integration of the 'Green' PLA closed-loop ecosystem (synthesis, modification, and chemical recycling) paired with a massive SKU range that spans consumer FDM, industrial resins, and medical-grade orthotics.

Market & Competition

Target Customers

Consumer-grade 3D printing enthusiasts (makers), educational institutions, industrial manufacturing firms, dental labs, and medical rehabilitation centers.

Industry Verticals

["Additive Manufacturing","Healthcare & Medical (Orthotics, Dentistry, Implants)","Education & Research","Industrial Design & Prototyping","Agriculture (Biodegradable products)","Consumer Electronics & Wearables"]

Competitors

Polymaker; Hatchbox; Sunlu; Formlabs

Growth & Milestones

Growth Metrics

Reported 41.43% year-over-year revenue growth in H1 2024; recognized as a national 'Little Giant' enterprise in China.

Major Milestones

["Founded in 2002 focusing on biomaterials","Successfully listed on the New Third Board (NEEQ: 836514) in April 2016","Drafted the Chinese national standards for PLA 3D printing consumables","Launched iSUN3D customized footwear system for medical rehabilitation in 2020","Expanded global manufacturing with a major plant in Vietnam in 2019"]

Notable Customers

World Robot Olympiad (WRO); Bambulab users; Maker community; Clinical Orthopedic Centers

Recent coverage of eSUN

Why this company matters

eSUN differentiates itself from other filament suppliers through its 'Green Closed-Loop' PLA industrial chain. The company synthesizes, modifies, applies, and chemically recycles bio-based polymers, turning waste PLA back into refined-grade lactic acid. This vertical integration spans from raw material production to finished consumables, giving it cost and sustainability advantages over competitors like Polymaker and Sunlu that rely on external resin suppliers.

The company's core technologies cover polymer material extrusion (MEX) and vat photopolymerization (VPP-SLA). Its product range includes the W200 water-washable resin, PETG-ESD for electrostatic discharge applications, and high-speed filaments optimized for fast FDM printers. eSUN also holds what it describes as the world's first patent for bio-based photopolymer resins and served as the primary drafting unit for China's national standards on PLA 3D printing consumables.

eSUN targets a broad customer base: consumer makers, educational institutions, industrial manufacturers, dental labs, and medical rehabilitation centers. Notable partners include the World Robot Olympiad and Bambu Lab users. In healthcare, the company launched the iSUN3D customized footwear system in 2020 for orthopedic applications. Its global distribution network spans over 100 countries through platforms like Amazon and Alibaba.

A key strategic moat is eSUN's ability to chemically recycle PLA, which few competitors can do at scale. However, the company faces competitive pressure from lower-cost generic filaments and from Formlabs in the resin segment. Its listing on China's NEEQ board and recognition as a national 'Little Giant' enterprise signal institutional credibility, but the $15 million in disclosed funding is modest relative to global peers.